Literature DB >> 10072493

B cell response after MMTV infection: extrafollicular plasmablasts represent the main infected population and can transmit viral infection.

C Ardavín1, P Martín, I Ferrero, I Azcoitia, F Anjuère, H Diggelmann, F Luthi, S Luther, H Acha-Orbea.   

Abstract

The immune response to mouse mammary tumor virus (MMTV) relies on the presentation of an MMTV-encoded superantigen by infected B cells to superantigen-specific T cells. The initial extrafollicular B cell differentiation involved the generation of B cells expressing low levels of B220. These B220low B cells corresponded to plasmablasts that expressed high levels of CD43 and syndecan-1 and were CD62 ligand- and IgD-. Viral DNA was detected nearly exclusively in these B220low B cells by PCR, and retroviral type-A particles were observed in their cytoplasm by electron microscopy. An MMTV transmission to the offspring was also achieved after transfer of B220low CD62 ligand- CD43+ plasmablasts into noninfected females. These data suggest that B220low plasmablasts, representing the bulk of infected B cells, are capable of sustaining viral replication and may be involved in the transmission of MMTV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072493

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche.

Authors:  Stéphane Chevrier; Céline Genton; Axel Kallies; Alexander Karnowski; Luc A Otten; Bernard Malissen; Marie Malissen; Marina Botto; Lynn M Corcoran; Stephen L Nutt; Hans Acha-Orbea
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

2.  Critical role of dendritic cells in mouse mammary tumor virus in vivo infection.

Authors:  Maria Cecilia Courreges; Dalia Burzyn; Irene Nepomnaschy; Isabel Piazzon; Susan R Ross
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

3.  Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

Authors:  M Mpandi; L A Otten; C Lavanchy; H Acha-Orbea; D Finke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection.

Authors:  Rachael Racine; Madhumouli Chatterjee; Gary M Winslow
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

5.  Transforming growth factor beta enhances the glucocorticoid response of the mouse mammary tumor virus promoter through Smad and GA-binding proteins.

Authors:  Koldo Aurrekoetxea-Hernández; Elena Buetti
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

6.  The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells.

Authors:  Edward P Bowman; Nelly A Kuklin; Kenneth R Youngman; Nicole H Lazarus; Eric J Kunkel; Junliang Pan; Harry B Greenberg; Eugene C Butcher
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

7.  Identification of proteoglycans as the APRIL-specific binding partners.

Authors:  Karine Ingold; Adrian Zumsteg; Aubry Tardivel; Bertrand Huard; Quynh-Giao Steiner; Teresa G Cachero; Fang Qiang; Leonid Gorelik; Susan L Kalled; Hans Acha-Orbea; Paul D Rennert; Jürg Tschopp; Pascal Schneider
Journal:  J Exp Med       Date:  2005-04-25       Impact factor: 14.307

8.  Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.

Authors:  Spyridon Stavrou; Daniel Crawford; Kristin Blouch; Edward P Browne; Rahul M Kohli; Susan R Ross
Journal:  PLoS Pathog       Date:  2014-05-22       Impact factor: 6.823

9.  Differential immune response associated to malaria outcome is detectable in peripheral blood following Plasmodium yoelii infection in mice.

Authors:  Isabel G Azcárate; Patricia Marín-García; Alí N Kamali; Susana Pérez-Benavente; Antonio Puyet; Amalia Diez; José M Bautista
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.